United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer and BioNTech expect to release a new Covid-19 booster shot designed to protect against the XXB.1.5 and XXB.1.6 variants.

Pfizer Expects Signoff For New Covid Boosters As Soon As This Month. Here's What To Know—And Why They're Needed

A powerful tornado last month flattened a warehouse at the drug maker's Rocky Mount, North Carolina facility, and destroyed the plant's utilities.

Pfizer CEO: Damaged Plant Could Lead to Shortages

Pfizer Inc. (NYSE:PFE ) Q2 2023 Results Conference Call August 1, 2023 10:00 AM ET Company Participants Chris Stevo - SVP and Chief IR Officer Dr. Albert Bourla - Chairman and CEO Dave Denton - CFO Dr. Mikael Dolsten - Chief Scientific Officer and President, Pfizer R&D Angela Hwang - Chief Commercial Officer and President, Global Biopharmaceuticals Business Aamir Malik - Chief Business Innovation Officer Dr. Chris Boshoff - Chief Oncology R&D Officer Conference Call Participants Nicole Germino - Truist Securities Umer Raffat - Evercore Evan Seigerman - BMO Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Louise Chen - Cantor Mohit Bansal - Wells Fargo Trung Huynh - Credit Suisse Colin Bristow - UBS Kerry Holford - Berenberg Geoff Meacham - Bank of America Tim Anderson - Wolfe Research Carter Gould - Barclays Steve Scala - Cowen David Risinger - Leerink Partners Andrew Baum - Citi Chris Schott - JPMorgan Rajesh Kumar - HSBC Michelle Rivera - inThought Research Operator Good day, everyone, and welcome to Pfizer's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded.

Pfizer Inc. (PFE) Q2 2023 Earnings Call Transcript

Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023.

Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines

Drugmaker Pfizer's Q2 earnings showed mixed results. EPS beat analyst expectations but revenue declined on falling demand for its COVID products.

Pfizer Q2 Revenue Misses Expectations as COVID Product Demand Slumps

JetBlue Airways

Uber

After today's close, Advanced Micro Devices (AMD) will be the latest important tech stock reporting, and will join Starbucks (SBUX).

Uber, Pfizer, JetBlue Beat Q2 Earnings, Miss Sales

Broadcom

Essex Property Trust

FedEx

Home Depot

Oracle

Vici Properties

This Tech dividend stock has become overvalued. I explain why taking gains is extremely important in any market. I offer 1 SWAN dividend replacement.

Sell This Overhyped AI Dividend Stock And Buy This SWAN Instead

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer (PFE) Reports Q2 Earnings: What Key Metrics Have to Say

Pfizer (PFE) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $2.04 per share a year ago.

Pfizer (PFE) Surpasses Q2 Earnings Estimates

Pfizer Inc (NYSE:PFE) reduced its full-year sales forecast by $1 billion following a decline in sales for Covid-related products. The pharmaceutical firm faced challenges in the second quarter as sales of its Covid pill and other key products underperformed, raising concerns about the company's ability to achieve its full-year sales guidance of $21.5 billion.

Pfizer slashes full-year sales forecast by $1B amidst decline in Covid-related product sales

Pfizer stock fell early Tuesday after the company reported massive sales and earnings declines amid lower demand for Covid products.

Pfizer Stock Dips As Waning Demand For Covid Products Slashes Sales In Half

The company is rolling out 19 products or new uses within 18 months, CEO Albert Bourla said.

Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall

Bristol-Myers

Chevron

NextEra Energy

T-Mobile US

Travelers

Verizon

The allure of discounted blue-chip stocks shines brighter than ever amid the complex mosaic of the stock market. With the stock market witnessing a rise driven by a handful of names, the flip side reveals several stocks lagging behind indices.

Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023

Pfizer Inc. PFE, -0.03% stock fell premarket Tuesday, after the drug giant's second-quarter earnings fell sharply from a year ago as sales of its COVID vaccine and antiviral tumbled to drive a more than 50% decline in revenue. The company posted net income of $2.327 billion, or 41 cents a share, for the quarter, down 77% from $9.906 billion, or $1.73 a share, in the year-earlier period.

Pfizer's stock falls premarket as earnings fall sharply amid lower sales for its COVID vaccine and antiviral

Pfizer is in a transition period as it pivots away from its blockbuster Covid vaccine and drug Paxlovid while the world emerges from the pandemic.

Pfizer beats on earnings, but revenue misses as Covid product sales plummet

Pfizer Inc on Tuesday fell short of Wall Street estimates for quarterly revenue, hit by declining sales of its COVID-19 products. Total revenue for the second quarter at $12.73 billion missing analysts' estimates of $13.27 billion, according to Refinitiv data.

Pfizer misses quarterly revenue estimates as COVID product sales decline

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2023. The company narrowed its 2023 revenue guidance(4) range to $67 to $70 billion, while maintaining its outlook for Adjusted diluted EPS(3) of $3.25 to $3.45. The second-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline can be found at www.pfizer.com. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chai.

Pfizer Reports Second-Quarter 2023 Results

There is no proven treatment for long Covid-19, which can cause a range of debilitating symptoms in millions of Americans.

NIH to test Pfizer's Paxlovid, other treatments as potential long Covid therapies

The U.S. National Institutes of Health (NIH) said on Monday that it had launched mid-stage clinical trials to test at least four treatments, including Pfizer's Paxlovid, in patients with symptoms of long COVID.

US NIH launches long-COVID trials of Pfizer's Paxlovid, other therapies

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.

How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?

Diageo

On Tuesday comes big oil, booze and sausage rolls, with BP PLC (LSE:BP.) and Greggs.

BP, Greggs and Diageo results due on Tuesday, plus Pfizer in US

Costco

Visa

You often hear investors out looking for essential blue-chip stocks, but what does that mean exactly? Blue chip stocks tend to be big, recognizable names.

If You Can Only Buy 1 Blue-Chip Stock, It Better Be One of These Names

AstraZeneca

Merck

Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare.

3 Pharma Stocks to Buy for Their Promising Progress

AstraZeneca plc (LON: AZN) was in focus on Friday after the pharma giant announced a deal worth up to $1.0 billion with its U.S. peer Pfizer Inc (NYSE: PFE). Details of the AstraZeneca-Pfizer deal The London-listed firm is buying a group of preclinical gene therapies from Pfizer to expand its footprint in rare diseases.

AstraZeneca reveals a $1.0 billion deal with Pfizer

Moderna

Novavax

Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.

News for Pfizer Stock (PFE)